Beskrywing

The multiple myeloma drug market in China in terms of revenue is set to grow by US$ 2 miljard tydens 2021-2027, groei teen 'n saamgestelde jaarlikse groeikoers (CAGR) van 18.8% gedurende die voorspellingsperiode, volgens die data- en ontledingsmaatskappy StrategyHelix.

Die verslag verskaf up-to-date markgrootte data vir tydperk 2017-2020 en voorspel tot 2027 covering key market aspects like sales value for multiple myeloma drug. The China multiple myeloma drug market is segmented on the basis of region. By region, it is categorized into Central South China, East China, North China, Northeast China, Northwest China, and Southwest China.

The report has profiled some of the key players of the market such as I-MAB Biopharma Co. Bpk., Janssen Biotech Inc., Karyopharm Therapeutics Inc., Sanofi S.A., Takeda Pharmaceutical Co. Bpk.

Die verslag is 'n waardevolle hulpbron vir maatskappye en organisasies wat in hierdie bedryf aktief is. It provides a cohesive picture of the multiple myeloma drug market to help drive informed decision making for industry executives, beleidmakers, akademies, en ontleders.

Verslag Omvang

Streek: Central South China, East China, North China, Northeast China, Northwest China, and Southwest China
Jare oorweeg: hierdie verslag dek die tydperk 2017 aan 2027

Sleutelvoordele vir belanghebbendes

Get a comprehensive picture of the China multiple myeloma drug market
Bepaal groeisektore en -neigings vir belegging
Understand what the future of the multiple myeloma drug market in China looks like
Identifiseer die mededingende landskap en geleentheidsvenster

INHOUDSOPGAWE

1. Markdefinisie
2. Navorsingsmetodologie
3. Markdata & Outlook
3.1 Markwaarde
3.2 Markwaarde Voorspelling
4. Multiple Myeloma Drug Market by Region
4.1 Central South China
4.2 East China
4.3 North China
4.4 Northeast China
4.5 Northwest China
4.6 Southwest China
5. Maatskappy profiele
5.1 I-MAB Biopharma Co., Bpk.
5.2 Janssen Biotech, Inc.
5.3 Karyopharm Therapeutics Inc.
5.4 Sanofi S.A.
5.5 Takeda Pharmaceutical Co. Bpk.
6. Bylaag
6.1 Oor StrategyHelix
6.2 Vrywaring